View Press Releases

MedPharm collaborates with Mosanna to develop new drug to tackle Metabolic Obstructive Sleep Apnea

September 20, 2022

MedPharm, a global provider of contract topical and transdermal formulation development and manufacturing services, is pleased to announce that it will support Swiss Biotech company, Mosanna Therapeutics, in the development of a nasal spray (MOS-118) aimed at treating Metabolic Obstructive Sleep Apnea (MOSA). 

The collaboration will focus on advancing MOS-118 into clinical development. Mosanna is developing MOS-118 to prevent the airway from collapsing during sleep in a disease that affects up to 1 billion globally. The repeated partial or complete obstruction of the upper airway during sleep is associated with adverse metabolic and cardiovascular events and can severely impact the quality of life for patients.

MedPharm will precisely engineer a product capable of delivering MOS-118 in a convenient spray, via the nose, to act locally in the upper airway overnight. 

Commenting on the partnership, MedPharm’s President & Chief Executive Officer, Eugene Ciolfi, said: “MedPharm’s primary mission is to support the development of life-changing therapeutics, and Mosanna’s nasal spray is a promising opportunity to do just that. We are excited to work with their team of experienced industry leaders to realize MOS-118’s potential with the end goal of improving the quality of life for those living with Metabolic Obstructive Sleep Apnea.”

MedPharm’s proprietary nasal testing models will be used to optimize the formulation and delivery of the product into the nasal cavity.      

Continuous positive airway pressure (CPAP) is the most common way of treating MOSA currently, however, studies have shown that at least 30% of patients do not tolerate this form of treatment*. There are currently no pharmaceutical treatments available so a well-tolerated, relatively painless nasal spray could transform the way the disease is treated by providing a much-needed alternative to patients. 

Dr. Jonathan Talbot, CEO from Mosanna added: “MedPharm is world-renowned for its dermal and transdermal capabilities including intranasal delivery routes so was a clear first choice for this project. I am also excited by the potential this partnership creates for additional projects on the horizon for Mosanna.”

MedPharm supports clients around the world from early-stage development through to the commercialization of their innovations, with a focus on topical and transdermal products. Find out more about its services here. 



About MedPharm

MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm’s experts excel at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm also offers innovative solutions for ophthalmic and airway preparations recognised for their scientific rigour by regulators and investors. MedPharm has fully established R&D centres in the USA and UK and has its global HQ in Guildford, UK.

About Mosanna Therapeutics 

Mosanna is a Swiss Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. We carefully select innovative medicines for further development using the best contract research organisations in the specific specialised field. Our first goal is to bring an effective and well tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea patients. 

Media Contact 


Danny McIver-